ClinicalTrials.gov
ClinicalTrials.gov Menu

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02452554
Recruitment Status : Active, not recruiting
First Posted : May 22, 2015
Last Update Posted : August 7, 2018
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : March 1, 2019
  Study Completion Date : No date given